T-Lymphocyte sub-populations in orbito-ocular granulocytic sarcoma (OOGS) and acute myelocytic leukemia (AML): A preliminary study

1993 ◽  
Vol 10 (3) ◽  
Author(s):  
Ayhan O. Çavdar ◽  
Emel Babacan ◽  
Sevgi GÖzdasoglu ◽  
GÜlsan Yavuz ◽  
Emel Ünal ◽  
...  
Keyword(s):  
T Lymphocyte ◽  
Granulocytic Sarcoma ◽  
Acute Myelocytic Leukemia ◽  
Myelocytic Leukemia ◽  
Preliminary Study

Granulocytic Sarcoma of Testis Preceding Acute Myelocytic Leukemia

1988 ◽  
Vol 43 (5) ◽  
pp. 310-312 ◽  
Author(s):  
Hidenori Kawashima ◽  
Wataru Sakamoto ◽  
Takaaki Nishijima ◽  
Masato Hanada ◽  
Katsushi Mori ◽  
...  
Keyword(s):  
Granulocytic Sarcoma ◽  
Acute Myelocytic Leukemia ◽  
Myelocytic Leukemia

Orbital granulocytic sarcoma: an unusual presentation of acute myelocytic leukemia

2003 ◽  
Vol 33 (2) ◽  
pp. 136-139 ◽  
Author(s):  
Rebecca Stein-Wexler ◽  
Sandra L. Wootton-Gorges ◽  
Daniel C. West
Keyword(s):  
Granulocytic Sarcoma ◽  
Unusual Presentation ◽  
Acute Myelocytic Leukemia ◽  
Myelocytic Leukemia

scholarly journals Granulocytic Sarcoma (Chloroma)

Blood ◽  
1970 ◽  
Vol 35 (3) ◽  
pp. 361-369 ◽  
Author(s):  
PETER H. WIERNIK ◽  
ARTHUR A. SERPICK
Keyword(s):  
Chest Wall ◽  
Granulocytic Sarcoma ◽  
Acute Monocytic Leukemia ◽  
Reticulum Cell ◽  
Acute Myelocytic Leukemia ◽  
Reticulum Cell Sarcoma ◽  
Partial Regression ◽  
Monocytic Leukemia ◽  
Myelocytic Leukemia ◽  
Leukemia Diagnosis

Abstract Four patients with granulocytic sarcoma are described. Granulocytic sarcoma of the cheek occurred in one patient 10 months before the diagnosis of acute myelocytic leukemia could be made. Another patient had multiple bone and dural granulocytic sarcomas 17 months before she developed acute myelocytic leukemia. One patient had a breast granulocytic sarcoma and acute myelocytic leukemia diagnosis simultaneously, and a fourth patient developed a chest wall granulocytic sarcoma 11-½ months after the diagnosis of acute monocytic leukemia. The cheek and chest wall granulocytic sarcomas responded completely to antileukemic chemotherapy but subsequently recurred. Radiotherapy effected a permanent complete remission of the chest wall sarcoma, and partial regression of the bone granulocytic sarcomas in another case. The possibility that acute myelocytic leukemic, granulocytic sarcoma and reticulum cell sarcoma are variations of the same disease is suggested and discussed.

scholarly journals Arabinosyl Cytosine: A Useful Agent in the Treatment of Acute Leukemia in Adults

Blood ◽  
1968 ◽  
Vol 32 (4) ◽  
pp. 507-523 ◽  
Author(s):  
ROSE RUTH ELLISON ◽  
JAMES F. HOLLAND ◽  
MARISE WEIL ◽  
CLAUDE JACQUILLAT ◽  
MICHEL BOIRON ◽  
...  
Keyword(s):  
Remission Rate ◽  
Hemoglobin Level ◽  
Lymphocytic Leukemia ◽  
Acute Myelocytic Leukemia ◽  
Pyrimidine Nucleoside ◽  
Myelocytic Leukemia ◽  
Daily Dose ◽  
Significant Superiority ◽  
Infusion Duration ◽  
Arabinosyl Cytosine

Abstract Arabinosyl cytosine (ara-C), a synthetic pyrimidine nucleoside related to the normal metabolites cytidine and deoxycytidine, has been found capable of producing marrow remission at tolerable doses in acute myelocytic and acute lymphocytic leukemia in adults. There were 16 per cent remissions complete in all aspects, 3 per cent complete except for hemoglobin level, and 6 per cent partial remissions among 180 adults with acute myelocytic leukemia treated with any one of 8 variants of infusion duration or daily dose of ara-C. Twenty-four per cent of 37 adults with acute lymphocytic or unclassified leukemia had complete or partial remissions. The comparison of 1, 4, 12 and 24 hours infusion of ara-C (to total dose tolerated) does not show significant superiority for any one group. The complete remission rate with 1 or 12 hour infusions, however, is 25 per cent (superior to that obtained with 6-mercaptopurine) and the recommended schedule of treatment for ara-C based on these data is, therefore, daily infusions of 100 or 50 mg./m.2 in one hour for approximately 3 to 6 weeks followed by maintenance therapy of once weekly subcutaneous injection of 30 mg./m.2 of ara-C. Platelet transfusions should be available when ara-C is used.

Different mechanisms lead to a karyotypically identical t(20;21) in myelodysplastic syndrome and in acute myelocytic leukemia

2003 ◽  
Vol 140 (1) ◽  
pp. 13-17 ◽  
Author(s):  
Caterina Matteucci ◽  
Roberta La Starza ◽  
Barbara Crescenzi ◽  
Silvia Romoli ◽  
Alessandra Santoro ◽  
...  
Keyword(s):  
Myelodysplastic Syndrome ◽  
Acute Myelocytic Leukemia ◽  
Myelocytic Leukemia

Dermatomyositis associated with acute myelocytic leukemia

2009 ◽  
Vol 30 (5) ◽  
pp. 671-673 ◽  
Author(s):  
Ankit Shrivastav ◽  
Varun Kumar ◽  
Jyotirmoy Pal
Keyword(s):  
Acute Myelocytic Leukemia ◽  
Myelocytic Leukemia
Sign in / Sign up

Export Citation Format

Share Document